Wed Feb 9 2011 8:45:48 AM EST Kirk already involved !!
BusinessWire, GlobeNewswire and PR Newswire News
ZIOPHARM Oncology Inc ZIOP:NASDAQ
Intrexon Appoints Vice President of Alliance Management for Human Therapeutics
BusinessWire
8:45 AM ET
Intrexon Corporation, a next generation synthetic biology company, today announced the appointment of Cary P. Moxham, Ph.D., as VP of Alliance Management for its Human Therapeutics alliances. Dr. Moxham's leadership activities will be focused, first and foremost, on Intrexon's exclusive channel partnership with ZIOPHARM Oncology, Inc., which was announced on January 6, 2011.
Dr. Moxham was most recently Senior Director, Alliance Management at Gilead Sciences, Inc., a role in which he served as the primary contact with multiple partner companies. During this lengthy tenure, Dr. Moxham led the management of governance committees and working group meetings to maximize adherence with established time lines and deliverables, including liaising with Legal, IP, Finance, R&D, and Commercial personnel. Prior to serving in Alliance Management, Dr. Moxham was Senior Director of Clinical Research at Gilead where he managed the Clinical Operations group based in Durham, NC responsible for execution of development programs in HIV and HBV. Dr. Moxham received his Ph.D. in Biochemical Pharmacology at State University of New York at Stony Brook, and a Bachelors of Science in Biology and Chemistry at Union College in Schenectady. His post-doctoral fellowship and subsequent project leadership at Burroughs Wellcome, Co./Glaxo Wellcome, Inc., led to recruitment by Triangle Pharmaceuticals, Inc., where he held leadership and management roles within Clinical Research and Business Development/Operations. Dr. Moxham served as the primary contact for R&D information in support of du e diligence preceding Gilead's acquisition of Triangle in 2003. Dr. Moxham is an accomplished clinical R&D scientist with numerous peer-reviewed publications and manuscripts.
"I became very intrigued with Intrexon after being introduced to the company's ability to induce and regulate in vivo protein expression through the dosing of a small molecule activator," states Dr. Moxham. "The novel therapeutic platform Intrexon has developed has the potential to solve a number of safety and efficacy challenges that have confronted the clinical production and dosing of recombinant therapeutic proteins. I am very excited to be a part of helping Intrexon and its channel partners harness the full potential of this industry-sh aping platform and realize the downstream commercial success of many high value therapeutics."
Randal J. Kirk, Intrexon's Chairman and CEO, comments, "I am very pleased we have an alliance executive with the experience and capabilities of Dr. Moxham managing our human therapeutics channel partnerships. He is already engaged on our new ZIOPHARM partnership and working closely with the joint committees on the planning and execution of our global alliance in oncology. I welcome him to the Intrexon team and look forward to the results of his leadership."
About Intrexon Corporation
Intrexon Corporation is a privately held synthetic biology company that employs modular DNA control systems to enhance capabilities, improve safety and lower cost in human therapeutics, protein production, industrial products and agricultural biotechnology. The company's advanced transgene engineering platform enables Better DNA(TM) by combining breakthroughs in DNA control systems with corresponding advancements in modular transgene design, assembly and optimization. The company is currently using these advanced capabilities to undertake foremost challenges across the spectrum for biological applications. More information about the company is available at www.DNA.com.
SOURCE: Intrexon Corporation Kirk already involved
Intrexon Corporation Robert Beech, 301-556-9812 rbeech@intrexon.com
Business Wire is a registered trademark of Business Wire. GlobeNewswire is a registered trademark of The NASDAQ OMX Group, Inc. PR Newswire is a registered trademark of PR Newswire Association, Inc.
Please do not reply to this e-mail from Wall Street on Demand. Wall Street on Demand and TD Ameritrade are separate unaffiliated companies and are not responsible for each other's service. For questions regarding your brokerage account, please contact TD Ameritrade Client Services at 1-800-669-3900.
To stop receiving this alert from TD Ameritrade, please click here to update your subscription settings. You may also unsubscribe from all of your alerts using the link above. As always, you can manage all of your alert settings by logging into your TD Ameritrade account and navigating to Research & Ideas > Alerts.
AI
